Our mission is to develop a topical therapeutic for dry eye that addresses cause.
The co-founder discovered ‘lacritin’, a natural tear protein selectively deficient in dry eye and yet when added topically to eyes of dry eye animals restores basal tearing without irritation and homeostasis of the eye surface. Improved homeostasis is revealed by reduced corneal staining and lacrimal gland inflammation. No other tear protein, nor dry eye drug, displays these properties.
Now, TearSolutions has developed a proprietary synthetic fragment of lacritin, Lacripep™. Lacripep™ is water soluble, stable in human tears, and equipotent to lacritin. Enrollment of a 201 patient phase 2 trial of Lacripep™ in Primary Sjogren’s Syndrome is now complete with results expected in 2020.